(Reuters) – Pfizer and German partner BioNTech said on Thursday that their vaccine to prevent flu and COVID-19 generated a strong immune response against the virus strains in early- to mid-stage trials.
The companies said they plan to start a late-stage trial in the coming months.
(Reporting by Manas Mishra in Bengaluru; Editing by Savio D’Souza)
